TY - JOUR
T1 - c-Jun-NH2-kinase-1 inhibition leads to antitumor activity in ovarian cancer
AU - Vivas-Mejia, Pablo
AU - Benito, Juliana Maria
AU - Fernandez, Ariel
AU - Han, Hee Dong
AU - Mangala, Lingegowda
AU - Rodriguez-Aguayo, Cristian
AU - Chavez-Reyes, Arturo
AU - Lin, Yvonne G.
AU - Carey, Mark S.
AU - Nick, Alpa M.
AU - Stone, Rebecca L.
AU - Kim, Hye Sun
AU - Claret, Francois Xavier
AU - Bornmann, William
AU - Hennessy, Bryan T.J.
AU - Sanguino, Angela
AU - Peng, Zhengong
AU - Sood, Anil K.
AU - Lopez-Berestein, Gabriel
PY - 2010/1/1
Y1 - 2010/1/1
N2 - Purpose: To show the functional, clinical, and biological significance of c-Jun-NH2-kinase (JNK)-1 in ovarian carcinoma. Experimental Design: Analysis of the impact of JNK on 116 epithelial ovarian cancers was conducted. The role of JNK in vitro and in experimental models of ovarian cancer was assessed. We studied the role of N-5-[4-(4-methyl piperazine methyl)-benzoylamido]-2-methylphenyl-4-[3-(4-methyl)-pyridyl]-2-pyrimidine amine (WBZ-4), a novel JNK inhibitor redesigned from imatinib based on targeting wrapping defects, in cell lines and in experimental models of ovarian cancer. Results: We found a significant association of pJNK with progression-free survival in the 116 epithelial ovarian cancers obtained at primary debulking therapy. WBZ-4 led to cell growth inhibition and increased apoptosis in a dose-dependent fashion in four ovarian cancer cell lines. In vivo, whereas imatinib had no effect on tumor growth, WBZ-4 inhibited tumor growth in orthotopic murine models of ovarian cancer. The antitumor effect was further increased in combination with docetaxel. Silencing of JNK-1 with systemically administered siRNA led to significantly reduced tumor weights compared with nonsilencing siRNA controls, indicating that indeed the antitumor effects observed were due to JNK-1 inhibition. Conclusions: These studies identify JNK-1 as an attractive therapeutic target in ovarian carcinoma and that the redesigned WBZ-4 compound should be considered for further clinical development.
AB - Purpose: To show the functional, clinical, and biological significance of c-Jun-NH2-kinase (JNK)-1 in ovarian carcinoma. Experimental Design: Analysis of the impact of JNK on 116 epithelial ovarian cancers was conducted. The role of JNK in vitro and in experimental models of ovarian cancer was assessed. We studied the role of N-5-[4-(4-methyl piperazine methyl)-benzoylamido]-2-methylphenyl-4-[3-(4-methyl)-pyridyl]-2-pyrimidine amine (WBZ-4), a novel JNK inhibitor redesigned from imatinib based on targeting wrapping defects, in cell lines and in experimental models of ovarian cancer. Results: We found a significant association of pJNK with progression-free survival in the 116 epithelial ovarian cancers obtained at primary debulking therapy. WBZ-4 led to cell growth inhibition and increased apoptosis in a dose-dependent fashion in four ovarian cancer cell lines. In vivo, whereas imatinib had no effect on tumor growth, WBZ-4 inhibited tumor growth in orthotopic murine models of ovarian cancer. The antitumor effect was further increased in combination with docetaxel. Silencing of JNK-1 with systemically administered siRNA led to significantly reduced tumor weights compared with nonsilencing siRNA controls, indicating that indeed the antitumor effects observed were due to JNK-1 inhibition. Conclusions: These studies identify JNK-1 as an attractive therapeutic target in ovarian carcinoma and that the redesigned WBZ-4 compound should be considered for further clinical development.
UR - http://www.scopus.com/inward/record.url?scp=74949089952&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=74949089952&partnerID=8YFLogxK
U2 - 10.1158/1078-0432.CCR-09-1180
DO - 10.1158/1078-0432.CCR-09-1180
M3 - Article
C2 - 20028751
AN - SCOPUS:74949089952
SN - 1078-0432
VL - 16
SP - 184
EP - 194
JO - Clinical Cancer Research
JF - Clinical Cancer Research
IS - 1
ER -